{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:03:43Z","timestamp":1788264223441,"version":"build-2803163510"},"reference-count":49,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100019944","name":"Sanofi Aventis Deutschland GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>We summarize here clinical and trial data on a once-daily administration of a single bolus to the meal with the largest expected postprandial glucose excursion (basal-plus), and comment on its clinical utility in the treatment of type 2 diabetes. A PubMed search of data published until September 2018 was taken into consideration and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Eighteen reports representing 15 studies were identified (age: 18\u201380 years; 50\u2013890 patients; follow-up: 8 days to 60 weeks). Data suggest basal-plus is efficacious for improving glycemic control, with a low incidence of (severe) hypoglycemia and minor increases in bodyweight. The timing of short-acting insulin administration and use of different monitoring\/titration approaches appear to have minimal impact. When compared with premixed insulin, basal-plus results in largely comparable outcomes. Compared with basal-bolus, it may result in non-inferior glycemic improvements with less weight gain, less hypoglycemia and fewer daily injections. A basal insulin\/glucagon-like peptide-1 receptor agonist fixed ratio combination may offer several advantages over the basal-plus regimen, at the cost of gastrointestinal side effects. We conclude that the stepwise introduction of short-acting insulin via the basal-plus strategy represents a viable alternative to a full basal-bolus regimen and may help to overcome barriers associated with multiple injections and anticipated complexity of the insulin regimen.<\/jats:p>","DOI":"10.1136\/bmjdrc-2019-000679","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T23:35:12Z","timestamp":1569972912000},"page":"e000679","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen"],"prefix":"10.1136","volume":"7","author":[{"given":"Jochen","family":"Seufert","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetoligy, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Borck","sequence":"additional","affiliation":[{"name":"Sanofi, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"2025073112252467000_7.1.e000679.1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"issue":"Suppl 1","key":"2025073112252467000_7.1.e000679.2","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1089\/dia.2010.0239","article-title":"Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts","volume":"13","author":"Monnier","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"2025073112252467000_7.1.e000679.3","doi-asserted-by":"crossref","unstructured":"Brod M , Kongs\u00f8 JH , Lessard S , et al . Psychological insulin resistance: patient beliefs and implications for diabetes management. Quality of Life Research 2009;18.doi:10.1007\/s11136-008-9419-1","DOI":"10.1007\/s11136-008-9419-1"},{"issue":"1 Suppl.","key":"2025073112252467000_7.1.e000679.4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1742-1241.2009.02176.x","article-title":"Barriers to insulin initiation and intensification and how to overcome them","volume":"63","author":"Kunt","year":"2009","journal-title":"Int J Clin Pract"},{"key":"2025073112252467000_7.1.e000679.5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","article-title":"Clinical inertia to insulin initiation and intensification in the UK: a focused literature review","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"2025073112252467000_7.1.e000679.6","first-page":"74","article-title":"Treatment of type 2 diabetes with biphasic insulin analogues","volume":"4","author":"Rizvi","year":"2016","journal-title":"Eur Med J Diabetes"},{"key":"2025073112252467000_7.1.e000679.7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1557-0843(07)80018-2","article-title":"The use of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: advantages and limitations","volume":"2","author":"Rizvi","year":"2007","journal-title":"Insulin"},{"key":"2025073112252467000_7.1.e000679.8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1463-1326.2008.00967.x","article-title":"Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs","volume":"10","author":"Lankisch","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"2025073112252467000_7.1.e000679.9","doi-asserted-by":"publisher","DOI":"10.4158\/EP10323.OR"},{"key":"2025073112252467000_7.1.e000679.10","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.1339"},{"key":"2025073112252467000_7.1.e000679.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2025073112252467000_7.1.e000679.12","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"2025073112252467000_7.1.e000679.13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4093\/dmj.2012.36.3.230","article-title":"Glycemic effects of once-a-day rapid-acting insulin analogue addition on a basal insulin analogue in Korean subjects with poorly controlled type 2 diabetes mellitus","volume":"36","author":"Choe","year":"2012","journal-title":"Diabetes Metab J"},{"key":"2025073112252467000_7.1.e000679.14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1185\/03007995.2016.1161609","article-title":"Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal","volume":"32","author":"Gross","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2025073112252467000_7.1.e000679.15","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0163"},{"key":"2025073112252467000_7.1.e000679.16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12225"},{"key":"2025073112252467000_7.1.e000679.17","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0900"},{"key":"2025073112252467000_7.1.e000679.18","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1988"},{"key":"2025073112252467000_7.1.e000679.19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4158\/EP14540.OR","article-title":"Comparison of basal insulin regimens on glycemic variability in NONCRITICALLY ill patients with type 2 diabetes","volume":"21","author":"Haw","year":"2015","journal-title":"Endocrine Practice"},{"key":"2025073112252467000_7.1.e000679.20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.diabet.2012.08.010","article-title":"Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the Osiris study","volume":"38","author":"Raccah","year":"2012","journal-title":"Diabetes Metab"},{"key":"2025073112252467000_7.1.e000679.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01459.x"},{"key":"2025073112252467000_7.1.e000679.22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/1753-0407.12312","article-title":"Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial","volume":"8","author":"Jin","year":"2016","journal-title":"J Diabetes"},{"key":"2025073112252467000_7.1.e000679.23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12528"},{"key":"2025073112252467000_7.1.e000679.24","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0014"},{"key":"2025073112252467000_7.1.e000679.25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/dia.2016.0176","article-title":"Premixed insulin analogue compared with Basal-Plus regimen for inpatient glycemic control","volume":"18","author":"Gracia-Ramos","year":"2016","journal-title":"Diabetes Technol Ther"},{"key":"2025073112252467000_7.1.e000679.26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12303"},{"key":"2025073112252467000_7.1.e000679.27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S2213-8587(13)70090-1","article-title":"Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP study): a randomised, treat-to-target clinical trial","volume":"2","author":"Rodbard","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073112252467000_7.1.e000679.28","doi-asserted-by":"publisher","DOI":"10.4158\/EP10367.OR"},{"key":"2025073112252467000_7.1.e000679.29","doi-asserted-by":"publisher","DOI":"10.1177\/014860719802200277"},{"key":"2025073112252467000_7.1.e000679.30","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0672"},{"key":"2025073112252467000_7.1.e000679.31","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02321"},{"key":"2025073112252467000_7.1.e000679.32","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.4.810"},{"key":"2025073112252467000_7.1.e000679.33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/dom.12211","article-title":"Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy-a combined analysis of 713 type 2 diabetic patients","volume":"16","author":"Seufert","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2025073112252467000_7.1.e000679.34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pcd.2015.05.003","article-title":"Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: a pooled analysis of four clinical trials","volume":"10","author":"Lankisch","year":"2016","journal-title":"Prim Care Diabetes"},{"key":"2025073112252467000_7.1.e000679.35","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0325-2"},{"key":"2025073112252467000_7.1.e000679.36","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1107"},{"key":"2025073112252467000_7.1.e000679.37","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1309"},{"key":"2025073112252467000_7.1.e000679.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-014-0698-4"},{"key":"2025073112252467000_7.1.e000679.39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.diabet.2013.09.002","article-title":"A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes","volume":"39","author":"Luzio","year":"2013","journal-title":"Diabetes Metab"},{"key":"2025073112252467000_7.1.e000679.40","first-page":"2566","article-title":"A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus","volume":"17","author":"Zhuang","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025073112252467000_7.1.e000679.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2009.02.009"},{"key":"2025073112252467000_7.1.e000679.42","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.561390"},{"key":"2025073112252467000_7.1.e000679.43","first-page":"42","article-title":"Body composition and epicardial fat in type 2 diabetes patients following insulin detemir versus insulin glargine initiation","volume":"48","author":"Elisha","year":"2016","journal-title":"Horm Metab Res"},{"key":"2025073112252467000_7.1.e000679.44","doi-asserted-by":"publisher","DOI":"10.4158\/EP09294.RA"},{"key":"2025073112252467000_7.1.e000679.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01580.x"},{"key":"2025073112252467000_7.1.e000679.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00746.x"},{"key":"2025073112252467000_7.1.e000679.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2007.11.013"},{"key":"2025073112252467000_7.1.e000679.48","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1252067"},{"key":"2025073112252467000_7.1.e000679.49","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E662"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2019-000679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:25:39Z","timestamp":1753989939000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2019-000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,10,1]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/bmjdrc-2019-000679"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2019-000679","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}